Literature DB >> 22806932

In vivo MRS and histochemistry of status epilepticus-induced hippocampal pathology in a juvenile model of temporal lobe epilepsy.

W Saskia van der Hel1, Pieter van Eijsden, Ineke W M Bos, Robin A de Graaf, Kevin L Behar, Onno van Nieuwenhuizen, Pierre N E de Graan, Kees P J Braun.   

Abstract

Childhood status epilepticus (SE) initiates an epileptogenic process that leads to spontaneous seizures and hippocampal pathology characterized by neuronal loss, gliosis and an imbalance between excitatory and inhibitory neurotransmission. It remains unclear whether these changes are a cause or consequence of chronic epilepsy. In this study, in vivo MRS was used in a post-SE juvenile rat model of temporal lobe epilepsy (TLE) to establish the temporal evolution of hippocampal injury and neurotransmitter imbalance. SE was induced in P21 rats by injection of lithium and pilocarpine. Four and eight weeks after SE, in vivo (1) H and γ-aminobutyric acid (GABA)-edited MRS of the hippocampus was performed in combination with dedicated ex vivo immunohistochemistry for the interpretation and validation of MRS findings. MRS showed a 12% decrease (p<0.0001) in N-acetylaspartate and a 15% increase (p=0.0226) in choline-containing compound concentrations, indicating neuronal death and gliosis, respectively. These results were confirmed by FluoroJade and vimentin staining. Furthermore, severe and progressive decreases in GABA (-41%, p<0.001) and glutamate (Glu) (-17%, p<0.001) were found. The specific severity of GABAergic cell death was confirmed by parvalbumin immunoreactivity (-68%, p<0.001). Unexpectedly, we found changes in glutamine (Gln), the metabolic precursor of both GABA and Glu. Gln increased at 4 weeks (+36%, p<0.001), but returned to control levels at 8 weeks. This decrease was consistent with the simultaneous decrease in glutamine synthase immunoreactivity (-32%, p=0.037). In vivo MRS showed gliosis and (predominantly GABAergic) neuronal loss. In addition, an increase in Gln was detected, accompanied by a decrease in glutamine synthase immunoreactivity. This may reflect glutamine synthase downregulation in order to normalize Gln levels. These changes occurred before spontaneous recurrent seizures were present but, by creating a pre-epileptic state, may play a role in epileptogenesis. MRS can be applied in a clinical setting and may be used as a noninvasive tool to monitor the development of TLE.
Copyright © 2012 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22806932     DOI: 10.1002/nbm.2828

Source DB:  PubMed          Journal:  NMR Biomed        ISSN: 0952-3480            Impact factor:   4.044


  6 in total

1.  Reproducibility and effect of tissue composition on cerebellar γ-aminobutyric acid (GABA) MRS in an elderly population.

Authors:  Zaiyang Long; Jonathan P Dyke; Ruoyun Ma; Chaorui C Huang; Elan D Louis; Ulrike Dydak
Journal:  NMR Biomed       Date:  2015-08-28       Impact factor: 4.044

2.  Preliminary evaluation of accelerated microscopic diffusional kurtosis imaging (μDKI) in a rodent model of epilepsy.

Authors:  Yang Ji; Dongshuang Lu; Limin Wu; Bensheng Qiu; Yi-Qiao Song; Phillip Zhe Sun
Journal:  Magn Reson Imaging       Date:  2018-10-20       Impact factor: 2.546

Review 3.  Neuroimaging biomarkers for epilepsy: advances and relevance to glial cells.

Authors:  Andre Obenaus
Journal:  Neurochem Int       Date:  2013-05-09       Impact factor: 3.921

4.  Individual differences in GABA content are reliable but are not uniform across the human cortex.

Authors:  Ian Greenhouse; Sean Noah; Richard J Maddock; Richard B Ivry
Journal:  Neuroimage       Date:  2016-06-09       Impact factor: 6.556

Review 5.  Preclinical Magnetic Resonance Imaging and Spectroscopy Studies of Memory, Aging, and Cognitive Decline.

Authors:  Marcelo Febo; Thomas C Foster
Journal:  Front Aging Neurosci       Date:  2016-06-29       Impact factor: 5.750

6.  Metabolic injury in a variable rat model of post-status epilepticus.

Authors:  Patrice S Pearce; Yijen Wu; Amedeo Rapuano; Kevin M Kelly; Nihal de Lanerolle; Jullie W Pan
Journal:  Epilepsia       Date:  2016-11-07       Impact factor: 5.864

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.